Sutro Biopharma, Inc.
General ticker "STRO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $46.0M (TTM average)
Sutro Biopharma, Inc. follows the US Stock Market performance with the rate: 39.8%.
Estimated limits based on current volatility of 2.6%: low 20.10$, high 21.17$
Factors to consider:
- Total employees count: 137 (-55.8%) as of 2025
- Top business risk factors: Clinical trial failure, No approved products, Operating losses, Regulatory and compliance, Manufacturing scale up
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.12$, 19.79$]
- 2026-12-31 to 2027-12-31 estimated range: [3.99$, 13.64$]
Financial Metrics affecting the STRO estimates:
- Negative: with PPE of -0.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -188.79 <= 0.28
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of -76.20 <= 18.97
- Positive: Investing cash flow per share per price, % of 47.95 > -0.64
Short-term STRO quotes
Long-term STRO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $153.73MM | $62.04MM | $102.48MM |
| Operating Expenses | $243.01MM | $300.50MM | $260.85MM |
| Operating Income | $-89.28MM | $-238.45MM | $-158.37MM |
| Non-Operating Income | $0.68MM | $13.36MM | $-32.81MM |
| Interest Expense | $12.57MM | $31.07MM | $38.21MM |
| R&D Expense | $180.43MM | $252.04MM | $166.42MM |
| Income(Loss) | $-88.60MM | $-225.10MM | $-191.18MM |
| Taxes | $18.19MM | $2.36MM | $-0.09MM |
| Net Income(Loss)* | $-106.79MM | $-227.46MM | $-191.09MM |
| Stockholders Equity | $149.65MM | $44.60MM | $-132.45MM |
| Assets | $470.74MM | $387.21MM | $173.83MM |
| Operating Cash Flow | $-111.62MM | $-191.54MM | $-177.23MM |
| Capital expenditure | $4.32MM | $3.10MM | $1.70MM |
| Investing Cash Flow | $-3.92MM | $218.51MM | $45.01MM |
| Financing Cash Flow | $137.55MM | $94.05MM | $0.04MM |
| Earnings Per Share** | $-17.75 | $-29.61 | $-22.49 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.